{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:51:49Z","timestamp":1792853509665,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00210-026-05582-5","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:12:48Z","timestamp":1781838768000},"page":"18655-18672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Repurposing approved drugs as ferroptosis modulators: a critical review of clinical trials in cancer and neurodegeneration"],"prefix":"10.1007","volume":"399","author":[{"given":"Mohammed","family":"Zayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Massoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas","family":"Elwakeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prehan","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Alammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nessma A. Abd","family":"El-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma W.","family":"Afifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-9994","authenticated-orcid":false,"given":"Byung-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"5582_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1525-1578(10)60574-0","volume":"7","author":"NA Alam","year":"2005","unstructured":"Alam NA, Olpin S, Rowan A, Kelsell D, Leigh IM, Tomlinson IP, Weaver T (2005) Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J Mol Diagn 7:437\u2013443","journal-title":"J Mol Diagn"},{"key":"5582_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/hep.510270510","volume":"27","author":"MJ Anasagasti","year":"1998","unstructured":"Anasagasti MJ, Martin JJ, Mendoza L, Obrador E, Estrela JM, McCuskey RS, Vidal-Vanaclocha F (1998) Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature. Hepatology 27:1249\u20131256","journal-title":"Hepatology"},{"key":"5582_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejca.2018.02.031","volume":"103","author":"TM-L Andersson","year":"2018","unstructured":"Andersson TM-L, Engholm G, Brink A-L, Pukkala E, Stenbeck M, Tryggvadottir L, Weiderpass E, Storm H (2018) Tackling the tobacco epidemic in the Nordic countries and lower cancer incidence by 1\/5 in a 30-year period\u2014the effect of envisaged scenarios changing smoking prevalence. Eur J Cancer 103:288\u2013298","journal-title":"Eur J Cancer"},{"key":"5582_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/360438","author":"A Ayala","year":"2014","unstructured":"Ayala A, Mu\u00f1oz MF, Arg\u00fcelles S (2014) Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. https:\/\/doi.org\/10.1155\/2014\/360438","journal-title":"Oxid Med Cell Longev"},{"key":"5582_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaneurol.2024.3733","volume":"82","author":"S Ayton","year":"2025","unstructured":"Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, Devos D, Ellis KA, Fazlollahi A, Fradette C (2025) Deferiprone in Alzheimer disease. JAMA Neurol 82:11\u201318","journal-title":"JAMA Neurol"},{"key":"5582_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","volume":"71","author":"MF Beal","year":"2014","unstructured":"Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71:543\u2013552","journal-title":"JAMA Neurol"},{"key":"5582_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1216733","volume":"10","author":"GL Beretta","year":"2023","unstructured":"Beretta GL, Zaffaroni N (2023) Radiotherapy-induced ferroptosis for cancer treatment. Frontiers in Molecular Biosciences 10:1216733","journal-title":"Frontiers in Molecular Biosciences"},{"key":"5582_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1476-5381.2011.01480.x","volume":"165","author":"RJ Bridges","year":"2012","unstructured":"Bridges RJ, Natale NR, Patel SA (2012) System xc\u207b cystine\/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol 165:20\u201334","journal-title":"Br J Pharmacol"},{"key":"5582_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.bbagen.2011.07.014","volume":"1820","author":"P Brissot","year":"2012","unstructured":"Brissot P, Ropert M, Le Lan C, Lor\u00e9al O (2012) Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 1820:403\u2013410","journal-title":"Biochim Biophys Acta"},{"key":"5582_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.637162","volume":"9","author":"X Chen","year":"2021","unstructured":"Chen X, Comish PB, Tang D, Kang R (2021a) Characteristics and biomarkers of ferroptosis. Front Cell Dev Biol 9:637162","journal-title":"Front Cell Dev Biol"},{"key":"5582_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D (2021b) Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol 18:280\u2013296","journal-title":"Nat Rev Clin Oncol"},{"key":"5582_CR12","doi-asserted-by":"publisher","DOI":"10.3892\/or.2023.8584","volume":"50","author":"Y Chen","year":"2023","unstructured":"Chen Y, Tao H, Wang F, Wu P, Gao J, Zhang X, He Z, Zhou Z, Jia Y (2023) Artesunate synergistically promotes sorafenib\u2011induced apoptosis and ferroptosis in non\u2011Hodgkin lymphoma cells through inhibition of the STAT3 pathway. Oncol Rep 50:147","journal-title":"Oncol Rep"},{"key":"5582_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41556-019-0305-6","volume":"21","author":"B Chu","year":"2019","unstructured":"Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, Song S, Tavana O, Gu W (2019) ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol 21:579\u2013591","journal-title":"Nat Cell Biol"},{"key":"5582_CR14","doi-asserted-by":"publisher","DOI":"10.4161\/23723556.2014.995047","volume":"2","author":"M Conrad","year":"2015","unstructured":"Conrad M, Friedmann Angeli JP (2015) Glutathione peroxidase 4 (Gpx4) and ferroptosis: what\u2019s so special about it? Mol Cell Oncol 2:e995047","journal-title":"Mol Cell Oncol"},{"key":"5582_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41589-019-0408-1","volume":"15","author":"M Conrad","year":"2019","unstructured":"Conrad M, Pratt DA (2019) The chemical basis of ferroptosis. Nat Chem Biol 15:1137\u20131147","journal-title":"Nat Chem Biol"},{"key":"5582_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-05272-5","volume":"6","author":"Y Dai","year":"2023","unstructured":"Dai Y, Chen Y, Mo D, Jin R, Huang Y, Zhang L, Zhang C, Gao H, Yan Q (2023) Inhibition of ACSL4 ameliorates tubular ferroptotic cell death and protects against fibrotic kidney disease. Commun Biol 6:907","journal-title":"Commun Biol"},{"key":"5582_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"MR de la Vega","year":"2018","unstructured":"de la Vega MR, Chapman E, Zhang DD (2018) Nrf2 and the hallmarks of cancer. Cancer Cell 34:21\u201343","journal-title":"Cancer Cell"},{"key":"5582_CR18","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","volume":"387","author":"D Devos","year":"2022","unstructured":"Devos D, Labreuche J, Rascol O, Corvol J-C, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, R\u016f\u017ei\u010dka E (2022) Trial of deferiprone in Parkinson\u2019s disease. N Engl J Med 387:2045\u20132055","journal-title":"N Engl J Med"},{"key":"5582_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1416","volume":"10","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Stockwell BR (2014) The role of iron and reactive oxygen species in cell death. Nat Chem Biol 10:9\u201317","journal-title":"Nat Chem Biol"},{"key":"5582_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060\u20131072","journal-title":"Cell"},{"key":"5582_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01297-7","volume":"8","author":"Y Du","year":"2022","unstructured":"Du Y, Guo Z (2022) Recent progress in ferroptosis: inducers and inhibitors. Cell Death Discov 8:501","journal-title":"Cell Death Discov"},{"key":"5582_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2013.282834","volume":"311","author":"MW Dysken","year":"2014","unstructured":"Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs M (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease. JAMA 311:33\u201344","journal-title":"JAMA"},{"key":"5582_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj9141","volume":"7","author":"S Egolf","year":"2021","unstructured":"Egolf S, Zou J, Anderson A, Simpson CL, Aubert Y, Prouty S, Ge K, Seykora JT, Capell BC (2021) Mll4 mediates differentiation and tumor suppression through ferroptosis. Sci Adv 7:eabj9141","journal-title":"Sci Adv"},{"key":"5582_CR24","doi-asserted-by":"crossref","unstructured":"Endale HT, Tesfaye W, Mengstie TA (2023) ROS induced lipid peroxidation and their role in ferroptosis. Front Cell Dev Biol 11:1226044","DOI":"10.3389\/fcell.2023.1226044"},{"key":"5582_CR25","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1038\/oncsis.2017.65","volume":"6","author":"Z Fan","year":"2017","unstructured":"Fan Z, Wirth A, Chen D, Wruck C, Rauh M, Buchfelder M, Savaskan N (2017) Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis 6:e371\u2013e371","journal-title":"Oncogenesis"},{"key":"5582_CR26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1021\/acscentsci.0c01592","volume":"7","author":"Y Fang","year":"2021","unstructured":"Fang Y, Chen X, Tan Q, Zhou H, Xu J, Gu Q (2021) Inhibiting ferroptosis through disrupting the NCOA4-FTH1 interaction: a new mechanism of action. ACS Cent Sci 7:980\u2013989","journal-title":"ACS Cent Sci"},{"key":"5582_CR27","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e10","volume":"36","author":"T Feng","year":"2025","unstructured":"Feng T, Zhang Y, Zheng G, Lv X, Yan D, Feng Y, Lou H (2025) Efficacy and safety of cisplatin combined with paclitaxel concurrent radiotherapy in patients with locally advanced cervical squamous cell carcinoma. J Gynecol Oncol 36:e10","journal-title":"J Gynecol Oncol"},{"key":"5582_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/17576180.2026.2624362","volume":"18","author":"C Fern\u00e1ndez-Metzler","year":"2026","unstructured":"Fern\u00e1ndez-Metzler C, Quadrini KJ, Amaravadi L, Cape S, Green J, Hays A, Kamphorst JJ, Laxmanan S, Pandey A, Qiu X, Rajapaksha RD, Hassanein M (2026) Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development. Bioanalysis 18:91\u2013109","journal-title":"Bioanalysis"},{"key":"5582_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molcel.2018.10.042","volume":"73","author":"M Gao","year":"2019","unstructured":"Gao M, Yi J, Zhu J, Minikes AM, Monian P, Thompson CB, Jiang X (2019) Role of mitochondria in ferroptosis. Mol Cell 73:354\u2013363. e353","journal-title":"Mol Cell"},{"key":"5582_CR30","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114351","volume":"13","author":"R Gao","year":"2021","unstructured":"Gao R, Kalathur RK, Coto\u2010Llerena M, Ercan C, Buechel D, Shuang S, Piscuoglio S, Dill MT, Camargo FD, Christofori G (2021) YAP\/TAZ and ATF4 drive resistance to sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med 13:e14351","journal-title":"EMBO Mol Med"},{"key":"5582_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/antiox7050062","author":"C Gaucher","year":"2018","unstructured":"Gaucher C, Boudier A, Bonetti J, Clarot I, Leroy P, Parent M (2018) Glutathione: antioxidant properties dedicated to nanotechnologies. Antioxidants (Basel). https:\/\/doi.org\/10.3390\/antiox7050062","journal-title":"Antioxidants (Basel)"},{"key":"5582_CR32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12:931\u2013947","journal-title":"Nat Rev Drug Discov"},{"key":"5582_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4143\/crt.2016.572","volume":"50","author":"J Guo","year":"2018","unstructured":"Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, Dai X, Li Z, Wu G (2018) Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat 50:445\u2013460","journal-title":"Cancer Res Treat"},{"key":"5582_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA (2015) Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27:211\u2013222","journal-title":"Cancer Cell"},{"key":"5582_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2023.03.016","volume":"79","author":"F He","year":"2023","unstructured":"He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, Karin M (2023) ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol 79:362\u2013377","journal-title":"J Hepatol"},{"key":"5582_CR36","first-page":"141","volume":"1","author":"SA Holstein","year":"2001","unstructured":"Holstein SA, Hohl RJ (2001) Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1:141\u2013149","journal-title":"Mol Cancer Ther"},{"key":"5582_CR37","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI124049","volume":"130","author":"K Hu","year":"2020","unstructured":"Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H (2020) Suppression of the SLC7A11\/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Invest 130:1752\u20131766","journal-title":"J Clin Invest"},{"key":"5582_CR38","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1101\/gad.275891.115","volume":"30","author":"M Jennis","year":"2016","unstructured":"Jennis M, Kung C-P, Basu S, Budina-Kolomets A, Leu J-J, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 30:918\u2013930","journal-title":"Genes Dev"},{"key":"5582_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang S-J, Su T, Hibshoosh H, Baer R, Gu W (2015) Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520:57\u201362","journal-title":"Nature"},{"key":"5582_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22:266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"14_supplement","key":"5582_CR41","doi-asserted-by":"publisher","first-page":"P7. 060","DOI":"10.1212\/wnl.84.14_supplement.p7.060","volume":"84","author":"R Kaji","year":"2015","unstructured":"Kaji R, Kuzuhara S, Iwasaki Y, Okamoto K, Nakagawa M, Imai T, Takase T, Shimizu H, Tashiro K (2015) Ultra-high dose methylcobalamin (E0302) prolongs survival of ALS: report of 7 years\u2019 randomised double-blind, phase 3 clinical trial (ClinicalTrials. gov NCT00444613)(P7. 060). Neurology 84:P7. 060https:\/\/doi.org\/10.1212\/wnl.84.14_supplement.p7.060","journal-title":"Neurology"},{"key":"5582_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-981-15-7305-7_2","volume-title":"Therapeutic Applications of Honey and its Phytochemicals: Volume II","author":"A Khan","year":"2020","unstructured":"Khan A, Alshahrani S, Arafah A, Qamar W, Shoaib A, Wali AF, Amin I, Alqahtani SS, Rehman MU (2020) Possible therapeutic potential of flavonoids and phenolic acids from honey in age-related neurodegenerative diseases via targeting NAD+ degradation. Therapeutic Applications of Honey and its Phytochemicals: Volume II. Springer, pp 19\u201343"},{"key":"5582_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-018-0288-x","volume":"38","author":"P Koppula","year":"2018","unstructured":"Koppula P, Zhang Y, Zhuang L, Gan B (2018) Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun 38:1\u201313","journal-title":"Cancer Commun"},{"key":"5582_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29905-1","volume":"13","author":"P Koppula","year":"2022","unstructured":"Koppula P, Lei G, Zhang Y, Yan Y, Mao C, Kondiparthi L, Shi J, Liu X, Horbath A, Das M (2022) A targetable CoQ-FSP1 axis drives ferroptosis-and radiation-resistance in KEAP1 inactive lung cancers. Nat Commun 13:2206","journal-title":"Nat Commun"},{"key":"5582_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","volume":"6","author":"VA Kraft","year":"2019","unstructured":"Kraft VA, Bezjian CT, Pfeiffer S, Ringelstetter L, M\u00fcller C, Zandkarimi F, Merl-Pham J, Bao X, Anastasov N, K\u00f6ssl J (2019) GTP cyclohydrolase 1\/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci 6:41\u201353","journal-title":"ACS Cent Sci"},{"key":"5582_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031851","volume":"23","author":"RN Lamptey","year":"2022","unstructured":"Lamptey RN, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 23:1851","journal-title":"Int J Mol Sci"},{"key":"5582_CR47","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s13238-021-00841-y","volume":"12","author":"G Lei","year":"2021","unstructured":"Lei G, Mao C, Yan Y, Zhuang L, Gan B (2021) Ferroptosis, radiotherapy, and combination therapeutic strategies. Protein Cell 12:836\u2013857","journal-title":"Protein Cell"},{"key":"5582_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26444\/aaem\/94299","volume":"26","author":"AM Lewandowska","year":"2018","unstructured":"Lewandowska AM, Rudzki M, Rudzki S, Lewandowski T, Laskowska B (2018) Environmental risk factors for cancer-review paper. Ann Agric Environ Med 26:1\u20137","journal-title":"Ann Agric Environ Med"},{"key":"5582_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12094-021-02669-8","volume":"24","author":"S Li","year":"2022","unstructured":"Li S, Huang Y (2022) Ferroptosis: an iron-dependent cell death form linking metabolism, diseases, immune cell and targeted therapy. Clin Transl Oncol 24:1\u201312","journal-title":"Clin Transl Oncol"},{"key":"5582_CR50","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/molecules15031378","volume":"15","author":"J Li","year":"2010","unstructured":"Li J, Zhou B (2010) Biological actions of artemisinin: insights from medicinal chemistry studies. Molecules 15:1378\u20131397","journal-title":"Molecules"},{"key":"5582_CR51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41401-020-0478-3","volume":"42","author":"Z-j Li","year":"2021","unstructured":"Li Z-j, Dai H-q, Huang X-w, Feng J, Deng J-h, Wang Z-x, Yang X-m, Liu Y-j, Wu Y, Chen P-h (2021) Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin 42:301\u2013310","journal-title":"Acta Pharmacol Sin"},{"key":"5582_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.910292","volume":"13","author":"FJ Li","year":"2022","unstructured":"Li FJ, Long HZ, Zhou ZW, Luo HY, Xu SG, Gao LC (2022) System X(c)(-)\/GSH\/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy. Front Pharmacol 13:910292","journal-title":"Front Pharmacol"},{"key":"5582_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175913","volume":"955","author":"Q Li","year":"2023","unstructured":"Li Q, Chen K, Zhang T, Jiang D, Chen L, Jiang J, Zhang C, Li S (2023) Understanding sorafenib-induced ferroptosis and resistance mechanisms: implications for cancer therapy. Eur J Pharmacol 955:175913","journal-title":"Eur J Pharmacol"},{"key":"5582_CR54","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.molcel.2022.03.022","volume":"82","author":"D Liang","year":"2022","unstructured":"Liang D, Minikes AM, Jiang X (2022) Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell 82:2215\u20132227","journal-title":"Mol Cell"},{"key":"5582_CR55","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.chembiol.2020.02.005","volume":"27","author":"J Liu","year":"2020","unstructured":"Liu J, Kuang F, Kroemer G, Klionsky DJ, Kang R, Tang D (2020) Autophagy-dependent ferroptosis: machinery and regulation. Cell Chem Biol 27:420\u2013435","journal-title":"Cell Chem Biol"},{"key":"5582_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102677","volume":"62","author":"S Liu","year":"2023","unstructured":"Liu S, Zhang H-L, Li J, Ye Z-P, Du T, Li L-C, Guo Y-Q, Yang D, Li Z-L, Cao J-H (2023) Tubastatin A potently inhibits GPX4 activity to potentiate cancer radiotherapy through boosting ferroptosis. Redox Biol 62:102677","journal-title":"Redox Biol"},{"key":"5582_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/clon.2002.0076","volume":"14","author":"H Lukka","year":"2002","unstructured":"Lukka H, Hirte H, Fyles A, Thomas G, Elit L, Johnston M, Fung MF, Browman G (2002) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll Radiol) 14:203\u2013212","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"5582_CR58","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.3390\/cancers12113150","volume":"12","author":"SD Markowitsch","year":"2020","unstructured":"Markowitsch SD, Schupp P, Lauckner J, Vakhrusheva O, Slade KS, Mager R, Efferth T, Haferkamp A, Juengel E (2020) Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis. Cancers 12:3150","journal-title":"Cancers"},{"issue":"1","key":"5582_CR59","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, Patel MC, Spino M, Connelly J, Tricta F (2017) Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci Rep 7:1398https:\/\/doi.org\/10.1038\/s41598-017-01402-2","journal-title":"Sci Rep"},{"key":"5582_CR60","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","volume":"337","author":"DC McLachlan","year":"1991","unstructured":"McLachlan DC, Kruck T, Kalow W, Andrews D, Dalton A, Bell M, Smith W (1991) Intramuscular desferrioxamine in patients with Alzheimer\u2019s disease. Lancet 337:1304\u20131308","journal-title":"Lancet"},{"key":"5582_CR61","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.bbrc.2020.04.127","volume":"527","author":"S Miyake","year":"2020","unstructured":"Miyake S, Murai S, Kakuta S, Uchiyama Y, Nakano H (2020) Identification of the hallmarks of necroptosis and ferroptosis by transmission electron microscopy. Biochem Biophys Res Commun 527:839\u2013844","journal-title":"Biochem Biophys Res Commun"},{"key":"5582_CR62","doi-asserted-by":"crossref","unstructured":"Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, Petrault M, Gouel F, Jonneaux A, Dutheil M (2018) Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? Antioxid Redox Signal 29:742\u2013748","DOI":"10.1089\/ars.2017.7493"},{"key":"5582_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050804","author":"MS Mortensen","year":"2023","unstructured":"Mortensen MS, Ruiz J, Watts L (2023) Polyunsaturated fatty acids drive lipid peroxidation during ferroptosis. Cells. https:\/\/doi.org\/10.3390\/cells12050804","journal-title":"Cells"},{"key":"5582_CR64","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/1078-0432.CCR-17-1117","volume":"24","author":"EJ Mun","year":"2018","unstructured":"Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD (2018) Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res 24:266\u2013275","journal-title":"Clin Cancer Res"},{"key":"5582_CR65","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.phymed.2015.08.002","volume":"22","author":"E Ooko","year":"2015","unstructured":"Ooko E, Saeed ME, Kadioglu O, Sarvi S, Colak M, Elmasaoudi K, Janah R, Greten HJ, Efferth T (2015) Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 22:1045\u20131054","journal-title":"Phytomedicine"},{"key":"5582_CR66","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1200\/JCO.2025.43.16_suppl.6561","volume":"43","author":"UR Popat","year":"2025","unstructured":"Popat UR, Bassett RL, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Valdez B, Qazilbash MH, Champlin RE, Shpall EJ, Andersson BS (2025) Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: results of a phase 1\/2 study. J Clin Oncol 43:6561\u20136561","journal-title":"J Clin Oncol"},{"key":"5582_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104961","volume":"144","author":"MU Rehman","year":"2023","unstructured":"Rehman MU, Sehar N, Dar NJ, Khan A, Arafah A, Rashid S, Rashid SM, Ganaie MA (2023) Mitochondrial dysfunctions, oxidative stress and neuroinflammation as therapeutic targets for neurodegenerative diseases: an update on current advances and impediments. Neurosci Biobehav Rev 144:104961","journal-title":"Neurosci Biobehav Rev"},{"key":"5582_CR68","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J (2021) Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol 22:977\u2013990","journal-title":"Lancet Oncol"},{"key":"5582_CR69","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/nm.4407","volume":"23","author":"R Romero","year":"2017","unstructured":"Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, S\u00e1nchez-Rivera FJ (2017) Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med 23:1362\u20131368","journal-title":"Nat Med"},{"key":"5582_CR70","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"S Rottenberg","year":"2021","unstructured":"Rottenberg S, Disler C, Perego P (2021) The rediscovery of platinum-based cancer therapy. Nat Rev Cancer 21:37\u201350","journal-title":"Nat Rev Cancer"},{"key":"5582_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01969-z","volume":"9","author":"Q Ru","year":"2024","unstructured":"Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F (2024) Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduct Target Ther 9:271","journal-title":"Signal Transduct Target Ther"},{"key":"5582_CR72","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.tips.2023.07.007","volume":"44","author":"SK Ryan","year":"2023","unstructured":"Ryan SK, Ugalde CL, Rolland AS, Skidmore J, Devos D, Hammond TR (2023) Therapeutic inhibition of ferroptosis in neurodegenerative disease. Trends Pharmacol Sci 44:674\u2013688","journal-title":"Trends Pharmacol Sci"},{"key":"5582_CR73","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","volume":"336","author":"M Sano","year":"1997","unstructured":"Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease. N Engl J Med 336:1216\u20131222","journal-title":"N Engl J Med"},{"key":"5582_CR74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-3-030-62026-4_4","volume":"1301","author":"N Santana-Codina","year":"2021","unstructured":"Santana-Codina N, Gikandi A, Mancias JD (2021) The role of NCOA4-mediated ferritinophagy in ferroptosis. Adv Exp Med Biol 1301:41\u201357","journal-title":"Adv Exp Med Biol"},{"key":"5582_CR75","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jtho.2022.03.011","volume":"17","author":"S Scalera","year":"2022","unstructured":"Scalera S, Mazzotta M, Cortile C, Krasniqi E, De Maria R, Cappuzzo F, Ciliberto G, Maugeri-Sacc\u00e0 M (2022) KEAP1-mutant NSCLC: the catastrophic failure of a cell-protecting hub. J Thorac Oncol 17:751\u2013757","journal-title":"J Thorac Oncol"},{"key":"5582_CR76","doi-asserted-by":"publisher","first-page":"36021","DOI":"10.18632\/oncotarget.8651","volume":"7","author":"T Sehm","year":"2016","unstructured":"Sehm T, Fan Z, Ghoochani A, Rauh M, Engelhorn T, Minakaki G, D\u00f6rfler A, Klucken J, Buchfelder M, Ey\u00fcpoglu IY, Savaskan N (2016) Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. Oncotarget 7:36021\u201336033","journal-title":"Oncotarget"},{"key":"5582_CR77","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1021\/acscentsci.7b00589","volume":"4","author":"R Shah","year":"2018","unstructured":"Shah R, Shchepinov MS, Pratt DA (2018) Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS Cent Sci 4:387\u2013396","journal-title":"ACS Cent Sci"},{"key":"5582_CR78","volume":"8","author":"Y Shen","year":"2018","unstructured":"Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P (2018) Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res 8:916","journal-title":"Am J Cancer Res"},{"key":"5582_CR79","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1158\/1078-0432.CCR-22-3971","volume":"29","author":"L Shi","year":"2023","unstructured":"Shi L, Chen H, Chen K, Zhong C, Song C, Huang Y, Wang T, Chen L, Li C, Huang A, Qi S, Li H, Lu Y (2023) The DRD2 antagonist haloperidol mediates autophagy-induced ferroptosis to increase temozolomide sensitivity by promoting endoplasmic reticulum stress in glioblastoma. Clin Cancer Res 29:3172\u20133188","journal-title":"Clin Cancer Res"},{"key":"5582_CR80","doi-asserted-by":"publisher","first-page":"vii80","DOI":"10.1093\/neuonc\/noac209.305","volume":"24","author":"BS Skeie","year":"2022","unstructured":"Skeie BS, Bragstad S, Sarowar S, Behbahani M, Filippi C, Knisely J, Schulder M, Goplen D, Eide GE, Heggdal JI, Gruner R, Enger P\u00d8 (2022) CTNI-40. Phase I trial of sulfasalazine combined with stereotactic radiosurgery for recurrent glioblastoma: study protocol for NCT04205357. Neuro Oncol 24:vii80\u2013vii81","journal-title":"Neuro Oncol"},{"key":"5582_CR81","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41392-023-01606-1","volume":"8","author":"S Sun","year":"2023","unstructured":"Sun S, Shen J, Jiang J, Wang F, Min J (2023) Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transduct Target Ther 8:372","journal-title":"Signal Transduct Target Ther"},{"key":"5582_CR82","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/HEP.0000000000000390","volume":"80","author":"D Tang","year":"2024","unstructured":"Tang D, Kroemer G, Kang R (2024) Ferroptosis in hepatocellular carcinoma: from bench to bedside. Hepatology 80:721\u2013739","journal-title":"Hepatology"},{"key":"5582_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051033","author":"MA Tomeh","year":"2019","unstructured":"Tomeh MA, Hadianamrei R, Zhao X (2019) A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20051033","journal-title":"Int J Mol Sci"},{"key":"5582_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/ng849","volume":"30","author":"IP Tomlinson","year":"2002","unstructured":"Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406","journal-title":"Nat Genet"},{"issue":"5","key":"5582_CR85","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJ, Atefi M, Shirazi R, Wang X (2018) Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell 33(5):890","journal-title":"Cancer Cell"},{"key":"5582_CR86","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ (2017) Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547:453\u2013457","journal-title":"Nature"},{"key":"5582_CR87","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41589-022-01249-3","volume":"19","author":"AN von Krusenstiern","year":"2023","unstructured":"von Krusenstiern AN, Robson RN, Qian N, Qiu B, Hu F, Reznik E, Smith N, Zandkarimi F, Estes VM, Dupont M, Hirschhorn T, Shchepinov MS, Min W, Woerpel KA, Stockwell BR (2023) Identification of essential sites of lipid peroxidation in ferroptosis. Nat Chem Biol 19:719\u2013730","journal-title":"Nat Chem Biol"},{"key":"5582_CR88","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1097\/JTO.0b013e31826149ba","volume":"7","author":"HA Wakelee","year":"2012","unstructured":"Wakelee HA, Lee JW, Hanna NH, Traynor AM, Carbone DP, Schiller JH (2012) A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43\u20139006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol 7:1574\u20131582","journal-title":"J Thorac Oncol"},{"key":"5582_CR89","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000362888","volume":"41","author":"S Waldvogel-Abramowski","year":"2014","unstructured":"Waldvogel-Abramowski S, Waeber G, Gassner C, Buser A, Frey BM, Favrat B, Tissot JD (2014) Physiology of iron metabolism. Transfus Med Hemother 41:213\u2013221","journal-title":"Transfus Med Hemother"},{"key":"5582_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030334","volume":"18","author":"H Wang","year":"2002","unstructured":"Wang H, Xie Y (2025) Advances in ferroptosis research: a comprehensive review of mechanism exploration, drug development, and disease treatment. Pharmaceuticals (Basel) 18:334. https:\/\/doi.org\/10.3390\/ph18030334","journal-title":"Pharmaceuticals (Basel)"},{"key":"5582_CR91","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.celrep.2016.09.022","volume":"17","author":"S-J Wang","year":"2016","unstructured":"Wang S-J, Li D, Ou Y, Jiang L, Chen Y, Zhao Y, Gu W (2016) Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Rep 17:366\u2013373","journal-title":"Cell Rep"},{"key":"5582_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01753-y","volume":"9","author":"J Wang","year":"2023","unstructured":"Wang J, Wu N, Peng M, Oyang L, Jiang X, Peng Q, Zhou Y, He Z, Liao Q (2023) Ferritinophagy: research advance and clinical significance in cancers. Cell Death Discov 9:463","journal-title":"Cell Death Discov"},{"key":"5582_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-026-00416-5","volume":"7","author":"J Wang","year":"2026","unstructured":"Wang J, Guo D, Jiang S, Wu W, Gao X (2026) Targeting ferroptosis in cancer: from mechanistic insights to therapeutic approaches. Mol Biomed 7:20","journal-title":"Mol Biomed"},{"key":"5582_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040891","author":"K Weaver","year":"2022","unstructured":"Weaver K, Skouta R (2022) The selenoprotein glutathione peroxidase 4: from molecular mechanisms to novel therapeutic opportunities. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10040891","journal-title":"Biomedicines"},{"key":"5582_CR95","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3961\/jpmph.2010.43.6.459","volume":"43","author":"E Weiderpass","year":"2010","unstructured":"Weiderpass E (2010) Lifestyle and cancer risk. J Prev Med Public Health 43:459\u2013471","journal-title":"J Prev Med Public Health"},{"key":"5582_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2025.114562","volume":"250","author":"P Xie","year":"2025","unstructured":"Xie P, Qu T, Tang K, Huang Y, Zeng G, Yuan H, Xin Q, Zhao Y, Yang J, Zeng C, Wu X, Yang ST, Tang X (2025) Carbon nanoparticles-Fe(II) complex combined with sorafenib for ferroptosis-induced antitumor effects in triple-negative breast cancer. Colloids Surf B Biointerfaces 250:114562","journal-title":"Colloids Surf B Biointerfaces"},{"key":"5582_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102564","volume":"59","author":"X Xu","year":"2023","unstructured":"Xu X, Li Y, Wu Y, Wang M, Lu Y, Fang Z, Wang H, Li Y (2023) Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. Redox Biol 59:102564","journal-title":"Redox Biol"},{"key":"5582_CR98","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s11033-022-08048-y","volume":"50","author":"Y Xu","year":"2023","unstructured":"Xu Y, Zhao J, Zhao Y, Zhou L, Qiao H, Xu Q, Liu Y (2023b) The role of ferroptosis in neurodegenerative diseases. Mol Biol Rep 50:1655\u20131661","journal-title":"Mol Biol Rep"},{"key":"5582_CR99","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","volume":"6","author":"H-f Yan","year":"2021","unstructured":"Yan H-f, Zou T, Tuo Q-z, Xu S, Li H, Belaidi AA, Lei P (2021) Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther 6:49","journal-title":"Signal Transduct Target Ther"},{"key":"5582_CR100","doi-asserted-by":"publisher","first-page":"30033","DOI":"10.1038\/srep30033","volume":"6","author":"X Yu","year":"2016","unstructured":"Yu X, Long YC (2016) Crosstalk between cystine and glutathione is critical for the regulation of amino acid signaling pathways and ferroptosis. Sci Rep 6:30033","journal-title":"Sci Rep"},{"key":"5582_CR101","doi-asserted-by":"crossref","unstructured":"Zahra W, Rai SN, Birla H, Singh SS, Dilnashin H, Rathore AS, Singh SP (2020) The global economic impact of neurodegenerative diseases: opportunities and challenges. In: Keswani C (ed) Bioeconomy for sustainable development. Springer Singapore, Singapore, pp 333\u2013345","DOI":"10.1007\/978-981-13-9431-7_17"},{"key":"5582_CR102","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s12015-024-10811-6","volume":"21","author":"M Zayed","year":"2025","unstructured":"Zayed M, Jeong BH (2025) Adipose-derived mesenchymal stem cell secretome attenuates prion protein peptide (106\u2013126)-induced oxidative stress via Nrf2 activation. Stem Cell Rev Rep 21:589\u2013592","journal-title":"Stem Cell Rev Rep"},{"key":"5582_CR103","doi-asserted-by":"publisher","DOI":"10.1080\/01652176.2025.2569558","volume":"45","author":"M Zayed","year":"2025","unstructured":"Zayed M, Abdelrazek M, Jeong BH (2025) Ferroptosis in veterinary medicine: mechanisms, therapies, and unmet challenges. Vet Q 45:2569558","journal-title":"Vet Q"},{"key":"5582_CR104","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s13287-025-04511-2","volume":"16","author":"M Zayed","year":"2025","unstructured":"Zayed M, Elwakeel E, Ezzat P, Jeong B-H (2025b) Mesenchymal stem cell-derived exosomes as a potential therapeutic strategy for ferroptosis. Stem Cell Res Ther 16:368","journal-title":"Stem Cell Res Ther"},{"key":"5582_CR105","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s13679-025-00669-1","volume":"14","author":"M Zayed","year":"2025","unstructured":"Zayed M, Massoud A, Hassan F, Elwakeel E, Mahmoud Y, Jeong BH (2025c) Harnessing adipose ferroptosis: a promising novel pathway for obesity treatment. Curr Obes Rep 14:74","journal-title":"Curr Obes Rep"},{"key":"5582_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2026.104155","volume":"93","author":"M Zayed","year":"2026","unstructured":"Zayed M, Tayara H, Jeong B-H (2026) Ferroptosis-related mechanisms in prion diseases provide insights into neurodegeneration and reveal therapeutic implications. Redox Biology 93:104155","journal-title":"Redox Biology"},{"key":"5582_CR107","doi-asserted-by":"crossref","unstructured":"Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, Sirohi K, Li X, Wei Y, Lee H, Zhuang L, Chen G, Xiao ZD, Hung MC, Chen J, Huang P, Li W, Gan B (2018) BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20:1181\u20131192","DOI":"10.1038\/s41556-018-0178-0"},{"key":"5582_CR108","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/15376516.2022.2075297","volume":"33","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Tan Y, Liu S, Yin H, Duan J, Fan L, Zhao X, Jiang B (2023) Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis. Toxicol Mech Methods 33:47\u201355","journal-title":"Toxicol Mech Methods"},{"key":"5582_CR109","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.freeradbiomed.2023.09.013","volume":"208","author":"Z Zhao","year":"2023","unstructured":"Zhao Z (2023) Hydroxyl radical generations form the physiologically relevant Fenton-like reactions. Free Radic Biol Med 208:510\u2013515","journal-title":"Free Radic Biol Med"},{"key":"5582_CR110","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cac2.12250","volume":"42","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, Zhang C, Zhou F, Chen J, Zhang L (2022) Ferroptosis in cancer and cancer immunotherapy. Cancer Commun 42:88\u2013116","journal-title":"Cancer Commun"},{"key":"5582_CR111","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s10787-024-01439-6","volume":"32","author":"C Zhao","year":"2024","unstructured":"Zhao C, Yu Y, Yin G, Xu C, Wang J, Wang L, Zhao G, Ni S, Zhang H, Zhou B, Wang Y (2024) Sulfasalazine promotes ferroptosis through AKT-ERK1\/2 and P53-SLC7A11 in rheumatoid arthritis. Inflammopharmacology 32:1277\u20131294","journal-title":"Inflammopharmacology"},{"key":"5582_CR112","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41419-021-03998-w","volume":"12","author":"J Zheng","year":"2021","unstructured":"Zheng J, Sato M, Mishima E, Sato H, Proneth B, Conrad M (2021) Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis 12:698","journal-title":"Cell Death Dis"},{"key":"5582_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, Sun Y, Zeng F, Chen X, Deng G (2024) Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther 9:55","journal-title":"Signal Transduct Target Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05582-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:03:08Z","timestamp":1791540188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05582-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":113,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5582"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05582-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}